Glenmark Pharmaceuticals trades higher on the bourses

24 Aug 2012 Evaluate

Glenmark Pharmaceuticals is currently trading at Rs. 412.90, up by 0.75 points or 0.18 % from its previous closing of Rs. 412.15 on the BSE.

The scrip opened at Rs. 416.00 and has touched a high and low of Rs. 418.20 and Rs. 410.60 respectively. So far 17827 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 426.85 on 06-Aug-2012 and a 52 week low of Rs. 265.00 on 21-Dec-2011.

Last one week high and low of the scrip stood at Rs. 419.95 and Rs. 404.50 respectively. The current market cap of the company is Rs. 11192.69 crore.

The promoters holding in the company stood at 48.26% while Institutions and Non-Institutions held 38.90% and 12.84% respectively. 

The International Centre for Dispute Resolution (ICDR) has ruled in the favour of Glenmark Pharmaceuticals on the arbitration claim filed against the Napo Pharmaceuticals on August 8, 2012. ICDR has ruled that Glenmark’s exclusive rights to develop, commercialize and distribute Crofelmer through relief agencies into the 140 countries that comprise of the Glenmark’s territory. ICDR also has allotted Glenmark a span of two years to file for regulatory approval in the 140 countries in its territory, from the time Crofelmer is approved in India (on an indication basis by indication basis).

 The International Centre for Dispute Resolution also found Napo Pharmaceuticals of breaching the collaboration agreement by disclosing information concerning the manufacture of Crofelmer to Aptuit Laurus and enjoining Napo from disclosing such confidential information to third parties and from purchasing or obtaining Crofelmer from Aptuit Laurus .

Glenmark filed arbitration claim against Napo, seeking among other things, a ruling that Glenmark’s exclusive rights to develop, commercialize and distribute Crofelmer in 140 countries for treatment of diarrheal disease includes the exclusive rights to distribute through relief agencies in these countries and an injection prohibiting Napo from sharing confidential information concerning the manufacture of Crofelmer.

Glenmark Pharmaceuticals has an exclusive license from Napo Pharmaceuticals, to distribute and commercialize Crofelmer in 140 emerging countries including India for indication related to HIV, used in acute and pediatric diarrhea. Crofelmer is a novel, first in class anti-diarrheal agent that has a physiological and different mechanism of action from traditional anti-diarrheal agencies.

Glenmark Pharma Share Price

2029.60 22.70 (1.13%)
30-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1719.60
Dr. Reddys Lab 1265.95
Cipla 1491.40
Zydus Lifesciences 901.30
Lupin 2081.00
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×